Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
Sarepta Therapeutics to Present at Upcoming Investor Conferences
04:30pm, Wednesday, 02'nd Mar 2022
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will p
Sarepta (SRPT) Q4 Earnings Beat, DMD Drugs Sales Robust
03:16pm, Wednesday, 02'nd Mar 2022 Zacks Investment Research
Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the fourth quarter. The company also raises revenue guidance for the year. Stock down in after-market trading.
Sarepta Therapeutics (SRPT) Q4 2021 Earnings Call Transcript
06:00am, Wednesday, 02'nd Mar 2022 The Motley Fool
SRPT earnings call for the period ending December 31, 2021.
Sarepta Therapeutics (SRPT) Q4 2021 Earnings Call Transcript
06:00am, Wednesday, 02'nd Mar 2022 The Motley Fool
SRPT earnings call for the period ending December 31, 2021.
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q4 2021 Results - Earnings Call Transcript
04:16am, Wednesday, 02'nd Mar 2022 Seeking AlphaSarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q4 2021 Results - Earnings Call Transcript
11:16pm, Tuesday, 01'st Mar 2022
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q4 2021 Results - Earnings Call Transcript
Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates
10:55pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 5.96% and 6.48%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Sarepta down 4% after hours despite top and bottom line earnings beats
09:59pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Shares of Sarepta Therapeutics (SRPT) are down 4% in post-market trading despite its Q4 2021 earnings beating on both the top and bottom lines.
Sarepta Therapeutics Non-GAAP EPS of -$0.77 beats by $0.37, revenue of $201.46M beats by $2.98M
09:09pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Sarepta Therapeutics press release (SRPT): Q4 Non-GAAP EPS of -$0.77 beats by $0.37.Revenue of $201.46M (+38.8% Y/Y) beats by $2.98M.Fourth quarter 2021 net product revenues…
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments
09:05pm, Tuesday, 01'st Mar 2022 GlobeNewswire
Total revenues, which consist primarily of net product revenues and collaboration revenues, for the fourth quarter and full-year 2021 totaled $201.5…
Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates
07:10pm, Tuesday, 01'st Mar 2022
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 5.96% and 6.48%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener
01:50pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
12:51pm, Tuesday, 01'st Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Editas Gains On Resolution Of CRISPR Gene Editing Patent Case
Editas Medicine, Inc. (NASDAQ: EDIT) sai
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11:17pm, Monday, 28'th Feb 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on February 28, 2022 t
Sarepta Therapeutics Q4 2021 Earnings Preview
10:35pm, Monday, 28'th Feb 2022 Seeking Alpha
Sarepta Therapeutics (NASDAQ:SRPT) is scheduled to announce Q4 earnings results on Tuesday, March 1st, after market close.The consensus EPS Estimate is -$1.14 (+38.0% Y/Y) and…
